02005.HK
SSY Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.58
+0.19%Oct 29, 2026, 08:59 UTC
China’s National Medical Products Administration approved SSY Group Ltd.’s nanofloxacin malate for registration as an active pharmaceutical ingredient for use in marketed formulations.
Source:Oct 29, 2026, 08:33 UTC
China's National Medical Products Administration approved Shijiazhuang Pharmaceutical Group's nadifloxacin malate for registration as an active pharmaceutical ingredient for use in marketed formulations.
Source:Oct 26, 2026, 08:31 UTC
SSY Group Ltd. reported unaudited revenue of approximately HK$3.52 billion, gross profit of approximately HK$1.442 billion and profit attributable to shareholders of approximately HK$460 million for the nine months ended September 30, 2026.
Oct 22, 2026, 04:17 UTC
China's National Medical Products Administration approved SSY Group Ltd.'s labetalol hydrochloride as an active pharmaceutical ingredient for use in marketed formulations.
Source:Oct 15, 2026, 08:34 UTC
SSY Group Ltd. said it received a drug production registration approval from China’s National Medical Products Administration for 2% sodium cromoglicate eye drops, a single-dose product deemed to have passed consistency evaluation.
Source:Oct 8, 2026, 08:48 UTC
China’s National Medical Products Administration approved SSY Group Ltd.’s production registration for nimodipine oral solution (10 mL:60 mg), deemed to have passed consistency evaluation.
Sep 22, 2026, 08:56 UTC
SSY Group (02005.HK) repurchased 1 million of its own shares on September 22, 2026 at prices between HK$2.745 and HK$2.77 per share, for about HK$2.7624 million.
Source:Sep 10, 2026, 04:09 UTC
Shijiazhuang No.4 Pharmaceutical obtained production registration approval from China's National Medical Products Administration for its Letermovir Injection (12ml:240mg), a Category 4 chemical drug deemed to have passed consistency evaluation, used to prevent cytomegalovirus infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.
Source:Sep 2, 2026, 09:10 UTC
SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.
Source:Aug 26, 2026, 04:17 UTC
SSY Group Limited reported interim results for the six months ended June 2026, with net profit of HK$320 million, up 13% year-on-year, and revenue of HK$2.361 billion, up 9.9%.
Source:Aug 25, 2026, 08:53 UTC
SSY Group Limited received regulatory approval from China's National Medical Products Administration to market its Ozagrel Sodium small-volume injections (5ml:40mg and 2.5ml:20mg), classified as Category 3 chemical drugs, deemed to have passed consistency evaluation.
Source:Aug 20, 2026, 04:09 UTC
SSY Group Limited received a drug production registration certificate from China's National Medical Products Administration for its Vitamin K1 injection (1ml:10mg), a Class 3 chemical drug deemed equivalent to generic consistency evaluation.
Source:Aug 6, 2026, 08:42 UTC
Shijiazhuang No.4 Pharmaceutical Group announced it has obtained drug production registration approvals from China's National Medical Products Administration for 4 products, all deemed to have passed consistency evaluation.
Jul 23, 2026, 09:46 UTC
Huahai Pharmaceutical received a drug registration certificate from the National Medical Products Administration for its ferrous succinate tablets, used for the prevention and treatment of iron deficiency anemia.
Jul 23, 2026, 08:39 UTC
Shijiazhuang Yiling Pharmaceutical obtained drug production registration approvals from the China National Medical Products Administration for four chemical drugs (Class 4, deemed passing consistency evaluation).
Jul 21, 2026, 00:47 UTC
Shijiazhuang Yiling Pharmaceutical's gadobutrol active pharmaceutical ingredient registration was approved by China's National Medical Products Administration.
Source: